Target intelligence / Profile preview

Herpes simplex virus DNA replication machinery

Molecular classification
Other
01

Overview

"Herpes simplex virus DNA replication" is a biological process, not a discrete, single molecular target (such as a receptor, enzyme, or ion channel). The replication of herpes simplex virus (HSV), primarily HSV-1 and HSV-2, is mediated by a multisubunit complex of viral proteins (including origin binding protein UL9, single-stranded DNA binding protein ICP8, helicase-primase complex UL5/UL8/UL52, and DNA polymerase UL30/UL42) along with numerous interacting host proteins[1][3][5]. These proteins work together to recognize viral origins of replication, unwind DNA, synthesize RNA primers, and perform DNA polymerization, coordinating with repair and chromatin remodeling pathways[1][3][2][5]. Drugs targeting HSV replication, such as acyclovir, inhibit the viral DNA polymerase, a viral enzyme within this replication machinery. However, "herpes simplex virus replication" itself is not a single molecular entity and therefore is not considered a standard therapeutic "target" but rather a process targeted indirectly by drugs aimed at individual components (such as the viral DNA polymerase). Target assignment qualifications: - **is_incorrect** is true because "Herpes simplex virus replication" specifies a viral process, not a unique molecular target suitable for structured molecular target data collection. The correct molecular targets for drug intervention are individual viral proteins, especially the viral DNA polymerase (UL30), single-stranded binding protein (ICP8), and associated replication proteins[5][3][2]. - If the intention is to capture the actual druggable target, the entry should be changed to "Herpes simplex virus DNA polymerase" or a specific HSV replication protein[3][5].

Other names
HSV-1 DNA replication complexHerpes simplex virus replication complexHSV-1 replication machinery
02

Mechanism of action

Inhibition of viral DNA polymerase, leading to premature chain termination (e.g., acyclovir and derivatives); Inhibition of pyrophosphate binding site on DNA polymerase (e.g., foscarnet)

03

Biological functions

Viral genome replicationDNA repairViral transcription coordination
04

Disease associations

Infection
05

Safety considerations

Emergence of drug-resistant HSV strains, particularly in immunocompromised patientsPotential nephrotoxicity (for drugs like foscarnet and cidofovir)
06

Interacting drugs

Acyclovir

5 more in the full profile.

07

Biomarkers

Viral DNA levels (as measured by PCR)Expression of HSV-1 immediate early proteins (e.g., ICP4, ICP8)

Beyond the preview

Go deeper on Herpes simplex virus DNA replication machinery.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Herpes simplex virus DNA replication machinery.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call